Riverbridge Partners LLC raised its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 2.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 521,804 shares of the medical instruments supplier’s stock after acquiring an additional 10,381 shares during the quarter. Riverbridge Partners LLC owned approximately 0.71% of West Pharmaceutical Services worth $50,229,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the business. Stevens Capital Management LP acquired a new stake in West Pharmaceutical Services in the third quarter valued at $947,000. State Board of Administration of Florida Retirement System lifted its stake in West Pharmaceutical Services by 4.3% in the third quarter. State Board of Administration of Florida Retirement System now owns 92,082 shares of the medical instruments supplier’s stock valued at $8,864,000 after acquiring an additional 3,830 shares during the last quarter. Conestoga Capital Advisors LLC lifted its stake in shares of West Pharmaceutical Services by 120.7% during the 3rd quarter. Conestoga Capital Advisors LLC now owns 25,993 shares of the medical instruments supplier’s stock worth $2,502,000 after buying an additional 14,218 shares during the last quarter. Victory Capital Management Inc. lifted its stake in shares of West Pharmaceutical Services by 27.0% during the 3rd quarter. Victory Capital Management Inc. now owns 377,692 shares of the medical instruments supplier’s stock worth $36,357,000 after buying an additional 80,406 shares during the last quarter. Finally, Crossmark Global Holdings Inc. acquired a new stake in shares of West Pharmaceutical Services during the 3rd quarter worth about $1,009,000. Hedge funds and other institutional investors own 90.10% of the company’s stock.

A number of analysts have recently issued reports on WST shares. Jefferies Group LLC upgraded shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and raised their target price for the stock from $96.00 to $115.00 in a research note on Friday, September 15th. Bank of America Corporation cut shares of West Pharmaceutical Services from a “buy” rating to a “neutral” rating and set a $98.00 target price for the company. in a research note on Tuesday, October 17th. BidaskClub cut shares of West Pharmaceutical Services from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Zacks Investment Research upgraded shares of West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research note on Wednesday, September 27th. Finally, Stephens started coverage on shares of West Pharmaceutical Services in a research note on Tuesday, October 3rd. They set an “equal weight” rating and a $99.00 target price for the company. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $106.00.

Shares of West Pharmaceutical Services, Inc. (NYSE WST) traded down $0.69 during trading on Monday, reaching $100.26. 28,799 shares of the company’s stock traded hands, compared to its average volume of 504,216. West Pharmaceutical Services, Inc. has a twelve month low of $73.69 and a twelve month high of $103.36. The company has a quick ratio of 1.87, a current ratio of 2.59 and a debt-to-equity ratio of 0.15. The firm has a market cap of $7,495.83, a PE ratio of 43.51, a price-to-earnings-growth ratio of 2.15 and a beta of 1.14.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, October 26th. The medical instruments supplier reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.53 by $0.14. West Pharmaceutical Services had a net margin of 12.12% and a return on equity of 14.47%. The business had revenue of $398.20 million during the quarter, compared to analysts’ expectations of $386.02 million. During the same quarter in the previous year, the company earned $0.53 EPS. The business’s revenue was up 5.7% on a year-over-year basis. equities analysts forecast that West Pharmaceutical Services, Inc. will post 2.76 EPS for the current year.

TRADEMARK VIOLATION WARNING: “West Pharmaceutical Services, Inc. (WST) Holdings Increased by Riverbridge Partners LLC” was reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/west-pharmaceutical-services-inc-wst-holdings-increased-by-riverbridge-partners-llc/1682869.html.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.